The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Morten Orebo Holmström; Hans Carl Hasselbalch; Mads Hald Andersen

doi:10.1080/2162402X.2017.1358334

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Morten Orebo Holmström, Hans Carl Hasselbalch, Mads Hald Andersen^*

^*Corresponding author af dette arbejde

Hæmatologisk Afdeling

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

Abstract

Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.

Originalsprog	Engelsk
Artikelnummer	e1358334
Tidsskrift	OncoImmunology
Vol/bind	6
Udgave nummer	11
DOI	https://doi.org/10.1080/2162402X.2017.1358334
Status	Udgivet - 2 nov. 2017

Adgang til dokumentet

10.1080/2162402X.2017.1358334

Andre filer og links

http://www.scopus.com/inward/record.url?scp=85028527082&partnerID=8YFLogxK

Citationsformater

@article{9d032676a45442e08cbc014558084747,

title = "The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy",

abstract = "Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.",

keywords = "calreticulin, CD4 T-cells, Hematological cancer, JAK2, neoantigens",

author = "Holmstr{\"o}m, {Morten Orebo} and Hasselbalch, {Hans Carl} and Andersen, {Mads Hald}",

year = "2017",

month = nov,

day = "2",

doi = "10.1080/2162402X.2017.1358334",

language = "English",

volume = "6",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "11",

}

TY - JOUR

T1 - The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

AU - Holmström, Morten Orebo

AU - Hasselbalch, Hans Carl

AU - Andersen, Mads Hald

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.

AB - Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.

KW - calreticulin

KW - CD4 T-cells

KW - Hematological cancer

KW - JAK2

KW - neoantigens

UR - http://www.scopus.com/inward/record.url?scp=85028527082&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2017.1358334

DO - 10.1080/2162402X.2017.1358334

M3 - Article

C2 - 29147619

AN - SCOPUS:85028527082

SN - 2162-4011

VL - 6

JO - OncoImmunology

JF - OncoImmunology

IS - 11

M1 - e1358334

ER -

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater